Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74

Amphastar Pharmaceuticals, Inc.

2025-Q1 EPS reported $0.51 revenue$170,528,000

Net revenues $170.5M, down from $171.8M in Q1 2024.
GAAP net income $25.3M ($0.51 diluted EPS) vs $43.2M ($0.81) last year.
Adjusted non-GAAP net income $36.9M ($0.74 EPS) vs $55.3M ($1.04) prior year.
CEO cites BAQSIMI and Primatene MIST growth; FDA accepted insulin biosimilar AMP-004 application.
Company managing resources for efficient operations amid revenue decline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.